bioshares reported in it's newsletter today that acrux is well funded 25 million cash on hand.a steady stream of income can be expected now from milestone and royalty payments from sale of evamist(est $500,000 pa and growing very well)and from other future partners outside the usa,animal health products and from a male testosterone deal(bioshares estimated deal could be worth between $150 and 300 million us dollars to acrux)based on the above they stated that acrux is offering exceptional value to investors.
ACR Price at posting:
45.0¢ Sentiment: ST Buy Disclosure: Held
